In short
Bulevirtide is an innovative drug being studied in clinical trials for the treatment of chronic hepatitis D, a serious liver infection caused by the hepatitis D virus (HDV). This article explores the ongoing research into bulevirtide's effectiveness, safety, and potential to improve outcomes for patients with this challenging condition.
At a glance
- Drug Name
- Bulevirtide (also known as Hepcludex®, Myrcludex B)
- Target Condition
- Chronic Hepatitis D (HDV) infection
- Mechanism of Action
- Blocks virus entry into liver cells by targeting NTCP protein
- Administration
- Daily subcutaneous injection (2 mg or 10 mg)
- Primary Outcomes
- Reduction in HDV RNA levels, ALT normalization
- Secondary Outcomes
- Liver fibrosis improvement, prevention of complications (e.g., HCC)
- Treatment Duration
- Varies by study, often 96-240 weeks
- Safety Monitoring
- Adverse events, laboratory abnormalities, bile acid levels
- Patient Populations
- Adults with chronic HDV, including those with cirrhosis
- Ongoing Research
- Long-term efficacy, real-world effectiveness, immune responses
What is Bulevirtide?
Bulevirtide is a new medication used to treat chronic hepatitis D, which is considered the most severe form of viral hepatitis. It is also known by the brand name Hepcludex® and was previously called Myrcludex B during its development. Bulevirtide received conditional approval from the European Medicines Agency in July 2020, making it the first specific treatment available for chronic hepatitis D.
How Does Bulevirtide Work?
Bulevirtide works by blocking the entry of hepatitis B and D viruses into liver cells. It does this by binding to and inactivating a protein called NTCP (Na+-taurocholate cotransporting polypeptide), which normally helps these viruses enter liver cells. By preventing the viruses from entering liver cells, bulevirtide helps to reduce the amount of virus in the body and may slow down or stop liver damage.
What Conditions Does Bulevirtide Treat?
Bulevirtide is specifically approved for the treatment of chronic hepatitis D infection. Hepatitis D is a rare but severe form of viral hepatitis that only occurs in people who are also infected with hepatitis B virus. It can lead to rapid progression of liver disease, increasing the risk of cirrhosis (scarring of the liver) and liver cancer.
How is Bulevirtide Administered?
Bulevirtide is given as a daily subcutaneous injection, which means it is injected just under the skin. The typical dose is 2 mg per day. Some studies are also investigating a higher dose of 10 mg per day. Patients may need to continue treatment for several months or even years, depending on their response to the medication.
Effectiveness of Bulevirtide
The effectiveness of bulevirtide is measured in several ways:
- Virological response: This is typically defined as a significant decrease in the amount of hepatitis D virus in the blood (often a decrease of at least 2 log10 IU/mL) or when the virus becomes undetectable.
- Biochemical response: This refers to the normalization of liver enzyme levels, particularly ALT (alanine aminotransferase), which indicates reduced liver inflammation.
- Combined response: This occurs when a patient achieves both a virological and biochemical response.
Studies have shown that many patients achieve these responses within 48 weeks of starting treatment, with some maintaining the response even after stopping the medication.
Safety and Side Effects
Bulevirtide is generally well-tolerated, but like all medications, it can cause side effects. Common side effects may include:
- Injection site reactions (such as redness or swelling where the medication is injected)
- Increases in bile acid levels in the blood
Researchers are closely monitoring for any serious side effects or long-term safety concerns as more patients receive the medication.
Ongoing Research
Several clinical trials are currently underway to further study bulevirtide. These studies aim to:
- Evaluate the long-term effectiveness and safety of bulevirtide
- Investigate its effects on portal hypertension (high blood pressure in the liver's blood vessels) in patients with cirrhosis
- Study how the medication works in patients with different degrees of liver function
- Explore potential biomarkers that might predict treatment response
These ongoing studies will help doctors better understand how to use bulevirtide effectively and safely in different patient populations.